EP300 and non-Hodgkin lymphoma: Importantly, CCS1477 is the first inhibitor of CBP/p300 to be tested first in human clinical trials in AML, multiple myeloma and non-Hodgkin lymphoma (NCT04068597), and in castration-resistant prostate cancer (NCT03568656)47.